PARP inhibitor radiosensitization enhances anti-PD-L1 immunotherapy through stabilizing chemokine mRNA in small cell lung cancer

PARP inhibitor radiosensitization enhances anti-PD-L1 immunotherapy through stabilizing chemokine mRNA in small cell lung cancer

Abstract Immunotherapy (IO) is an effective treatment for various cancers; however, the benefits are modest for small cell lung cancer (SCLC). The poor response of SCLC to anti-PD-1/PD-L1 IO is due in part to the lack of cytotoxic T cells because of limited chemokine expression from SCLC tumors. Imm...

Full description

Bibliographic Details
Main Authors: Xiaozhuo Ran, Bell Xi Wu, Venkatasubramanian Vidhyasagar, Lifang Song, Xu Zhang, Reese Jalal Ladak, Mona Teng, Wail Ba-alawi, Vivek Philip, Housheng H. He, Nahum Sonenberg, Benjamin H. Lok
Format: Article
Language:English
Published: Nature Portfolio 2025-03-01
Series:Nature Communications
Online Access:https://doi.org/10.1038/s41467-025-57257-z

Internet

https://doi.org/10.1038/s41467-025-57257-z

Similar Items